Failure of omalizumab for treatment of severe adult atopic dermatitis
- 1 August 2005
- journal article
- research article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 53 (2) , 338-340
- https://doi.org/10.1016/j.jaad.2005.02.014
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Efficacy and tolerability of anti‐immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLARAllergy, 2004
- Efficacy and tolerability of anti‐immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate‐to‐severe) allergic asthmaAllergy, 2004
- Omalizumab treatment downregulates dendritic cell FcεRI expressionJournal of Allergy and Clinical Immunology, 2003
- Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthmaAnnals of Allergy, Asthma & Immunology, 2003
- Omalizumab is effective in the long-term control of severe allergic asthmaAnnals of Allergy, Asthma & Immunology, 2003
- Omalizumab and the immune system: an overview of preclinical and clinical dataAnnals of Allergy, Asthma & Immunology, 2002
- Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthmaJournal of Allergy and Clinical Immunology, 2001
- Ultraviolet A and melanoma: A reviewJournal of the American Academy of Dermatology, 2001
- Efficacy of Omalizumab, an Anti-immunoglobulin E Antibody, in Patients with Allergic Asthma at High Risk of Serious Asthma-related Morbidity and MortalityCurrent Medical Research and Opinion, 2001
- Treatment of Allergic Asthma with Monoclonal Anti-IgE AntibodyNew England Journal of Medicine, 1999